Molecular structure of Pitavastatin Lactone, CAS Number: 141750-63-2
Pitavastatin Lactone (CAS 141750-63-2)
See product citations (3)
Application:
Pitavastatin Lactone is a major phase 2 metabolite of pitavastatin, an inhibitor of HMG-CoA reductase
CAS Number:
141750-63-2
Purity:
≥95%
Molecular Weight:
403.45
Molecular Formula:
C25H22FNO3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Pitavastatin Lactone is a compound studied primarily in the field of organic chemistry and enzymology, particularly regarding its interactions with enzymes involved in lipid metabolism. It serves as a key molecule for understanding the structure-activity relationship within the class of compounds known as statins. Researchers investigate the conversion of Pitavastatin Lactone to its active hydroxy acid form. The lactone form itself is for studies on the stability and metabolism of statin compounds within biological systems. In addition, Pitavastatin Lactone is used in the synthesis of related analogs to explore the kinetics and mechanisms of statin derivatives. The compound is also a subject in the field of analytical chemistry, where the development of sensitive and specific detection methods for statin lactones in various matrices is a topic of interest.
Pitavastatin Lactone (CAS 141750-63-2) References
- Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. | Prueksaritanont, T., et al. 2002. Drug Metab Dispos. 30: 505-12. PMID: 11950779
- Role of P-glycoprotein in pharmacokinetics: clinical implications. | Lin, JH. and Yamazaki, M. 2003. Clin Pharmacokinet. 42: 59-98. PMID: 12489979
- Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. | Miners, JO., et al. 2002. Toxicology. 181-182: 453-6. PMID: 12505351
- Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. | Fujino, H., et al. 2003. Xenobiotica. 33: 27-41. PMID: 12519692
- Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans. | Yamada, I., et al. 2003. Xenobiotica. 33: 789-803. PMID: 12893526
- Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. | Kajinami, K., et al. 2003. Cardiovasc Drug Rev. 21: 199-215. PMID: 12931254
- Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. | Benet, LZ., et al. 2003. Curr Drug Metab. 4: 393-8. PMID: 14529371
- Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. | Hui, CK., et al. 2005. Br J Clin Pharmacol. 59: 291-7. PMID: 15752374
- Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. | Fujino, H., et al. 2004. Xenobiotica. 34: 961-71. PMID: 15801541
- Development and validation of a liquid chromatography-tandem mass spectrometric assay for pitavastatin and its lactone in human plasma and urine. | Tian, L., et al. 2008. J Chromatogr B Analyt Technol Biomed Life Sci. 865: 127-32. PMID: 18342583
- Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. | Saito, Y. 2009. Vasc Health Risk Manag. 5: 921-36. PMID: 19997573
- Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men. | Warrington, S., et al. 2011. Clin Drug Investig. 31: 735-43. PMID: 21877766
- Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study. | Qi, X., et al. 2013. J Pharm Biomed Anal. 72: 8-15. PMID: 23146221
- Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. | Malvestutto, CD., et al. 2014. J Acquir Immune Defic Syndr. 67: 390-6. PMID: 25202920
- Pitavastatin – pharmacological profile from early phase studies | Alberico L. Catapano. 2010. Atherosclerosis Supplements. 11: 3-7.
Inhibitor of:
HMGCR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Pitavastatin Lactone, 5 mg | sc-208177 | 5 mg | $204.00 |